We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
-5.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.54B
AUM Growth
-$303M
(-11%)
Cap. Flow
-$71.8M
Cap. Flow
% of AUM
-2.82%
Top 10 Holdings %
Top 10 Hldgs %
38.38%
Holding
180
New
5
Increased
27
Reduced
36
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$14M |
| 2 |
Intuitive Surgical
ISRG
|
+$11.4M |
| 3 |
Boston Scientific
BSX
|
+$9.19M |
| 4 |
AstraZeneca
AZN
|
+$8.8M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$8.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$19.5M |
| 2 |
McKesson
MCK
|
+$14.5M |
| 3 |
Medtronic
MDT
|
+$11M |
| 4 |
Eli Lilly
LLY
|
+$10.6M |
| 5 |
Illumina
ILMN
|
+$7.92M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.42% |
| 2 | Real Estate | 3.13% |
| 3 | Industrials | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
UnitedHealth
UNH
$383B
| $164M | 6.45% |
319,510
-10,516
| -3% | -$5.28M |
|
2
Amgen
AMGN
$209B
| $133M | 5.24% |
548,418
-26,500
| -5% | -$6.49M |
|
3
Gilead Sciences
GILD
$163B
| $102M | 4.01% |
1,650,765
-35,800
| -2% | -$2.22M |
|
|
4
Vertex Pharmaceuticals
VRTX
$122B
| $102M | 4% |
361,231
+52,347
| +17% | +$14M |
|
5
Johnson & Johnson
JNJ
$617B
| $91.7M | 3.6% |
516,652
| – | – |
|
6
AbbVie
ABBV
$455B
| $86.8M | 3.41% |
566,842
+18,698
| +3% | +$2.86M |
|
7
Regeneron Pharmaceuticals
REGN
$77.4B
| $84.5M | 3.32% |
142,864
-3,336
| -2% | -$2.17M |
|
|
8
AstraZeneca
AZN
$266B
| $74.3M | 2.92% |
562,371
+67,033
| +14% | +$8.8M |
|
|
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $69.9M | 2.75% |
876,089
-83,350
| -9% | -$7.89M |
|
10
Abbott
ABT
$183B
| $68.2M | 2.68% |
627,292
+8,515
| +1% | +$967K |
|
11
Bristol-Myers Squibb
BMY
$132B
| $60.3M | 2.37% |
782,735
+58,859
| +8% | +$4.48M |
|
12
Pfizer
PFE
$142B
| $59.4M | 2.33% |
1,132,103
-39,800
| -3% | -$2.03M |
|
|
13
Eli Lilly
LLY
$1.03T
| $57.2M | 2.25% |
176,432
-35,400
| -17% | -$10.6M |
|
14
Thermo Fisher Scientific
TMO
$214B
| $53M | 2.08% |
97,605
| – | – |
|
|
15
McKesson
MCK
$101B
| $52.4M | 2.06% |
160,722
-45,300
| -22% | -$14.5M |
|
16
Merck
MRK
$321B
| $50.3M | 1.98% |
552,122
-23,500
| -4% | -$2.08M |
|
17
Moderna
MRNA
$23B
| $46.9M | 1.84% |
328,524
| – | – |
|
18
Cigna
CI
$76.1B
| $45.6M | 1.79% |
173,106
+1,083
| +0.6% | +$279K |
|
19
Stryker
SYK
$133B
| $44.9M | 1.76% |
225,678
| – | – |
|
|
20
Illumina
ILMN
$31B
| $36.1M | 1.42% |
201,536
-31,010
| -13% | -$7.92M |
|
|
SGEN
21
DELISTED
Seagen Inc. Common Stock
SGEN
| $34.5M | 1.36% |
195,183
-135,378
| -41% | -$19.5M |
|
22
Danaher
DHR
$138B
| $31.6M | 1.24% |
140,499
-28,865
| -17% | -$6.65M |
|
23
Humana
HUM
$44B
| $29.9M | 1.17% |
63,794
+234
| +0.4% | +$104K |
|
|
24
Boston Scientific
BSX
$68.4B
| $29.6M | 1.16% |
795,215
+225,817
| +40% | +$9.19M |
|
25
Molina Healthcare
MOH
$10.2B
| $29.4M | 1.15% |
105,085
+10,560
| +11% | +$3.19M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Tekla Capital Management held 180 positions worth $2.54B, down 11% from $2.85B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Trading was light in Q2 2022: portfolio turnover was 4.4%. Tekla Capital Management opened 5 new positions and exited 3, leaving the 180-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.
- Tekla Capital Management's largest Q2 2022 buy was Lantheus: 127,092 shares worth $8.39M.
- Tekla Capital Management added most to Vertex Pharmaceuticals in Q2 2022, an estimated $14M increase.
- Tekla Capital Management's biggest Q2 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $19.5M.
- Tekla Capital Management fully exited Revvity in Q2 2022, selling an estimated $5.83M.
- Tekla Capital Management's ten largest holdings make up 38% of its $2.54B portfolio in Q2 2022.
- Tekla Capital Management opened 5 new positions and closed 3 in Q2 2022.
- Tekla Capital Management's portfolio value fell 11% quarter-over-quarter to $2.54B.
Based on Tekla Capital Management's 13F filing for Q2 2022, filed 29 Jul 2022.